Source: Journal of Clinical Oncology. Conference titles: Gastrointestinal Cancers Symposium. Unidade: FM
Subjects: PROGNÓSTICO, MUTAÇÃO GENÉTICA, ADENOCARCINOMAS, NEOPLASIAS PANCREÁTICAS (TERAPIA)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LINO, Aline Da Rocha et al. Role of second-line gemcitabine after FOLFIRINOX failure in advanced pancreatic adenocarcinoma: A retrospective analysis. Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://meeting.ascopubs.org/cgi/content/abstract/33/3_suppl/325?sid=7e455e95-85c7-4753-bb1d-a8742284537e. Acesso em: 01 nov. 2024. , 2015APA
Lino, A. D. R., Martins Junior, R. M., Abrahao, C. M., Moreira, R. B., Sousa, T. T. S. de, Gomes, J. R., et al. (2015). Role of second-line gemcitabine after FOLFIRINOX failure in advanced pancreatic adenocarcinoma: A retrospective analysis. Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://meeting.ascopubs.org/cgi/content/abstract/33/3_suppl/325?sid=7e455e95-85c7-4753-bb1d-a8742284537eNLM
Lino ADR, Martins Junior RM, Abrahao CM, Moreira RB, Sousa TTS de, Gomes JR, Alessandretti MB, Amarante MPF, Ferrian AM, Schutz FAB, Kawamura C, Schmerling R, Cruz MR, Peixoto RD'A, Machado MCC, Buzaid AC, Maluf FC. Role of second-line gemcitabine after FOLFIRINOX failure in advanced pancreatic adenocarcinoma: A retrospective analysis [Internet]. Journal of Clinical Oncology. 2015 ; 33( 3S ):[citado 2024 nov. 01 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/33/3_suppl/325?sid=7e455e95-85c7-4753-bb1d-a8742284537eVancouver
Lino ADR, Martins Junior RM, Abrahao CM, Moreira RB, Sousa TTS de, Gomes JR, Alessandretti MB, Amarante MPF, Ferrian AM, Schutz FAB, Kawamura C, Schmerling R, Cruz MR, Peixoto RD'A, Machado MCC, Buzaid AC, Maluf FC. Role of second-line gemcitabine after FOLFIRINOX failure in advanced pancreatic adenocarcinoma: A retrospective analysis [Internet]. Journal of Clinical Oncology. 2015 ; 33( 3S ):[citado 2024 nov. 01 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/33/3_suppl/325?sid=7e455e95-85c7-4753-bb1d-a8742284537e
